Gene therapy for visual loss: Opportunities and concerns

Progress in Retinal and Eye Research
Jia Hui LeeGuei-Sheung Liu

Abstract

Many clinical trials using gene therapy have shown significant therapeutic benefits and exceptional safety records. Increasing evidence is verifying the long sought-after promise that gene therapy will genetically 'cure' some severely disabling diseases. In particular, the first gene therapy bioproduct for RPE65-associated Leber's congenital amaurosis, which was approved by the US Food and Drug Administration in 2017, has provided tremendous encouragement to the field of gene therapy. Recent developments in genome editing technologies have significantly advanced our capability to precisely engineer genomes in eukaryotic cells. Programmable nucleases, particularly the CRISPR/Cas system, have been widely adopted in studies applying genome engineering therapy to ocular diseases with the hope of managing these diseases. In this review article, we summarize the current approaches that have been developed in the area of gene therapy for ocular disease. We also discuss the challenges and opportunities facing gene therapy for ocular diseases, as well as its prospects.

Citations

Oct 3, 2018·International Journal of Molecular Sciences·Youn-Shen BeeMing-Hong Tai
May 11, 2019·Accountability in Research·Karen M Meagher, Zubin Master
May 17, 2019·Expert Opinion on Drug Delivery·Francine Behar-Cohen
Sep 3, 2019·Current Eye Research·Tasneem Z Khatib, Keith R Martin
Jan 30, 2020·International Journal of Molecular Sciences·Lewis E FryRobert E MacLaren
May 18, 2020·Current Diabetes Reports·Jiang-Hui WangGuei-Sheung Liu
Mar 23, 2019·Frontiers in Public Health·Gemma A BilkeyKristen J Nowak
Jul 28, 2020·Expert Opinion on Emerging Drugs·Elio StrigliaMassimo Porta
Oct 23, 2020·Tissue Engineering. Part B, Reviews·Zhi ZhengHua Wei
Nov 3, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Paula I Fuller-CarterLivia S Carvalho
Apr 21, 2020·Progress in Retinal and Eye Research·Gustavo Barreto MeloEduardo Büchele Rodrigues
Jun 20, 2020·Progress in Retinal and Eye Research·Nicole WeisschuhBernd Wissinger
Jan 6, 2021·Asia-Pacific Journal of Ophthalmology·David XuAllen C Ho
Feb 18, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Xiangjun HeBo Feng
Feb 1, 2020·Progress in Retinal and Eye Research·Nadia Sukusu NielsenJan J Enghild
Jan 28, 2021·British Journal of Pharmacology·Xun ZhangXinhua Shu
Jun 25, 2020·Molecular Therapy. Methods & Clinical Development·Yuxi ChenZhou Songyang
Mar 11, 2021·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Fleur O'HareLauren N Ayton
Mar 11, 2021·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Monica L HuLauren N Ayton
Jul 11, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Fan-Li LinGuei-Sheung Liu
Jul 14, 2021·Translational Vision Science & Technology·Coralia LunaPedro Gonzalez
Nov 2, 2020·Progress in Retinal and Eye Research·Nathaniel K MullinBudd A Tucker
Aug 28, 2021·Genes·Saoud Al-KhuzaeiStephanie Halford
Aug 31, 2021·Ophthalmic Genetics·Di HuangFred K Chen
Sep 18, 2020·Current Gene Therapy·Nidhi PuranikJun-O Jin
Nov 25, 2021·Experimental and Therapeutic Medicine·Andreea Dana MoraruDaniel Constantin Branisteanu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Related Papers

Current Opinion in Ophthalmology
Daniel C ChungAlbert M Maguire
Nature Medicine
David Benjamin Turitz CoxFeng Zhang
Archivos de oftalmología de Buenos Aires
E Manzitti, A Damel
Revista de chirurgie, oncologie, radiologie, o. r. l., oftalmologie, stomatologie. Oftalmologie
D Enache
© 2022 Meta ULC. All rights reserved